Why the study?
Detection of cardiotoxicity associated with cancer treatment has shifted toward earlier subclinical detection, creating a need to evaluate evolving imaging techniques.
This review highlights the paradigm shift in cardio-oncology toward early detection of subclinical cardiotoxicity using advanced imaging techniques like global longitudinal strain and cardiac MRI.
Since the 1970s, there have been many paradigm shifts in the detection of cardiotoxicity associated with cancer treatment. These have included movement away from late sequelae of cancer treatment such as heart failure or decline in ejection fraction toward earlier detection of subclinical toxicity using echocardiographically derived global longitudinal strain and high sensitivity troponin assays. In addition to this, cardiac MRI has had an expanding role in detecting cardiotoxicity due to its reproducibility in left ventricular ejection fraction measurements and tissue characterization. This article summarizes the strengths and weaknesses of these imaging techniques in characterizing cardiotoxicity in patients receiving cancer therapy.
No takes yet. Share an insight, caveat, or question.
Jeanne M. DeCara (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: